Jefferies' Outlook on CVS Health
Jefferies has highlighted CVS Health as the leading large‑cap opportunity in the healthcare services sector following the company’s second‑quarter earnings reaction and broader market dislocations. Management has set an earnings‑per‑share floor of $8.44 for fiscal year 2027, and the firm expects a share‑repurchase programme to resume at the end of 2026 or early 2027, which should add further support to the stock. The brokerage rates CVS a Buy with a $120 price target, implying roughly 29 % upside from the prior closing price of $92.92.
Aetna, CVS’s health‑insurance arm, delivered approximately $2.4 billion of adjusted operating income in the second quarter and posted an 87.4 % medical benefit ratio. Core results, excluding certain adjustments, beat expectations, driven largely by Medicare performance, and Aetna has generated more than $2 billion of year‑over‑year operating‑income growth to date. Fiscal‑2027 Medicare Advantage bids incorporate higher utilization assumptions, and Jefferies expects better‑than‑expected member retention, a favourable mix, leading Star ratings and disciplined pricing to expand margins further.
In the Pharmacy & Consumer Wellness segment, same‑store prescription volumes rose 7 % year‑over‑year in the second quarter, supporting the CostVantage initiative. Cost‑based contracts are providing more consistent reimbursement, and fiscal‑2026 results have already exceeded forecasts. The Health Services segment faces FY2027 headwinds from 340B pricing pressure and a decline in Caremark membership, but Jefferies believes these challenges are already reflected in the $8.44 earnings floor and will be offset by growth in specialty prescriptions and improving delivery economics.
CVS generated roughly $10.6 billion of operating cash flow in the first half of the year, and management has lifted its fiscal‑2026 cash‑flow guidance to more than $11.5 billion. The company closed the second quarter with leverage below 3.3 times, positioning it for a possible buyback restart. The quarter’s financial performance was stronger than expected, with adjusted earnings of $2.58 per share on revenue of $106.1 billion, prompting an upgrade of the full‑year outlook. Moody’s subsequently moved its rating outlook to positive from stable, citing progress in the health‑insurance turnaround and the reduction in financial leverage.